Investigating and Characterizing the Immune Response to Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The immune system plays an important role in cancer, and there is evidence that different types of cancer treatment can elicit different responses from the body's immune system. This study is designed to look at immune markers in the blood and urine of patients undergoing four different types of prostate cancer treatment and compare the differences.
Patients who have elected Total Cryotherapy (freezing of the entire prostate), focal cryotherapy (freezing only the side of the prostate affected by cancer), Cyberknife stereotactic body radiation therapy (SBRT) and Radical Prostatectomy (removal of the entire prostate) for the treatment of their prostate cancer will be eligible to participate in this study. The study is expected to enroll 40 patients, 10 patients per treatment group. The study includes a screening visit during which the subject will provide informed consent, and provide a blood sample and a urine sample. At 2-3 weeks following their scheduled treatment, they will again provide another blood and urine sample. At their regularly scheduled follow up at 3 months, they will again provide another blood and urine sample. These samples are collected for research purposes only, and the costs will be covered by the study grant account, without any additional cost to the patient.
The investigators have determined that this study presents no more than minimal risk to patients due to the minimal risks involved with a blood draw and urine specimen collection.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Mineola, New York, United States, 11501
- NYU Winthrop Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is willing and able to freely sign informed consent to enroll in the study.
- Histologically proven Prostate Carcinoma.
- Undergoing total cryotherapy, focal cryotherapy, Cyberknife SBRT or radical prostatectomy for prostate cancer treatment.
Exclusion Criteria:
- Has previously had a radical prostatectomy for prostate cancer.
- Has previously received cryotherapy for prostate cancer.
- Previous treatment with chemotherapy within the past 6 months.
- Previous treatment with radiation within the past 18 months.
- Has evidence of metastatic disease.
- Has a current or history within the past 6 months of alcohol and/or substance abuse which would impair participation in the study.
- Has a major medical disorder (i.e. uncontrolled diabetes, significant hepatic, renal or hematological disorders, recent stroke or myocardial infarction), in the opinion of the urologist, is an illness or complication which is not consistent with the protocol requirements.
- Is not willing to undergo the necessary follow-up for the trial period.
- Has known immunologic disease, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Total Cyrotherapy of the Prostate
Patients who will undergo total cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
|
Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.
Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
|
|
ACTIVE_COMPARATOR: Focal Cryotherapy of the Prostate
Patients who will undergo focal cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
|
Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.
Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
|
|
ACTIVE_COMPARATOR: Cyberknife SBRT of the Prostate
Patients who will undergo Cyberknife SBRT of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post Cyberknife, 3 months post Cyberknife)
|
Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.
Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
|
|
ACTIVE_COMPARATOR: Radical Prostatectomy
Patients who will undergo a radical prostatectomy will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post surgery, 3 months post surgery)
|
Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.
Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the change in blood cytokine profile
Time Frame: Before treatment, 2-3 weeks post treatment, 3 months post treatment
|
Cytokines to be evaluated include but are not limited to: TNF-alpha, IL-1b, IL2, IL-2 CD25 Receptor Soluble, IFN-gamma, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 and IL-13.
|
Before treatment, 2-3 weeks post treatment, 3 months post treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aaron E Katz, MD, NYU
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-01696 (OTHER: NYU Langone Institutional Review Board)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.